RSS Urosphère Rss news Urosphère http://www.urosphere.com en Automne (TM) EmailAuteurDuRssaDefinir@aol.fr (urosphere) cecile.durand@urosphere.com (urosphere) http://blogs.law.harvard.edu/tech/rss 1440 object1-85http://www.urosphere.com/web/EN/22-actualites.php?id=85UROsphere present scientific results at EAU 27th annual congress (Paris, France, 24-26 February 2012) 

 It is with pleasure that we will meet you at the booth 1N24, level 1, hall Passy.

 

 

The following posters will be presented on Sunday, 26 February 2012 from 09h15 to 10h45.

  • Effect of a selective β3-adrenergic agonist (CL-316, 243) on cystometric parameters in conscious spinal cord injured female rats.

J.B. Beauval , V. Guilloteau , M. Capellini , A. Naudin , M. Guérard , P. Lluel , S. Palea , P. Rischmann , X. Gamé.

  • Dose-dependent effect of a selective β3 adrenoreceptor agonist (CL-316,243) on the bladder contractility and the micturition frequency in female rats.

J.B. Beauval, P. Lluel, M.A. Guardia-Llorens, V. Guilloteau, T.D. Westfall, S. Palea, X. Gamé.

 

 

]]>Auteur de ma newsMon, 06 Feb 2012 00:00:00 +010024 object1-302http://www.urosphere.com/web/EN/22-actualites.php?id=302UROsphere presents scientific results at the International Continence Society (ICS) annual meeting (Glasgow, United-Kingdom, 29 August - 2 September 2011) 

 

The following poster will be presented as a non discussed poster:

  • Effect of a selective beta3 adrenoreceptor agonist (CL-316, 243) on cystometric parameters in conscious and anesthetized female rats.

Beauval. JB, Lluel. P, Guardia-Llorens. M, Guilloteau. V, Westfall. T, Game. X, Palea. S.

 

UROsphere's top managers will be present during the meeting. If you wish to meet them, please contact us

 

]]>Auteur de ma newsWed, 03 Aug 2011 00:00:00 +020024 object1-285http://www.urosphere.com/web/EN/22-actualites.php?id=285UROsphere presents scientific results at 10th world congress on inflammation - Paris, June 25-29, 2011The following posters will be presented:

  • Pharmacological modulation of urinary bladder inflammation in a rat model of cyclophosphamide induced acute bladder pain. 

Augé. C, Chêne. G, Dubourdeau. M, Palea. S, Vergnolle. N, Lluel. P, Coelho. A.M

Poster presentation on Tuesday, June 28, 2011 - 12:00 to 14:00.

  • Evaluation of pro-resolving mediators during urinary bladder inflammation: effect of aspirin, ibuprofen and morphine.

Dubourdeau. M, Baillif. V, Augé. Chêne. G, Palea. P, Vergnolle. N, Lluel. P, Coelho. A.M.

Poster presentation on Tuesday, June 28, 2011 - 12:00 to 14:00.

 

UROsphere's top managers will be present during the meeting. If you wish to meet them, please contact us.

]]>Auteur de ma newsWed, 01 Jun 2011 00:00:00 +020024 object1-319http://www.urosphere.com/web/EN/22-actualites.php?id=319UROsphere present scientific results at AUA annual meeting (Washington DC, USA, 14-19 May 2011) 

 

 

The following podium will be presented:

  • Alterations in inflammatory mediators in a rat model of cyclophosphamide-induced acute visceral pain. 

             Céline Augé, Anne-Marie Coelho, Gérald Chêne, Marc Dubourdeau, Stefano Palea, Nathalie

             Vergnolle, Philippe Lluel.

            

             Podium Presentation on Monday, May 16, 2011 from 8:00 to 10:00.

 

The following moderated poster will be presented:

  • Naxopren and morphine reverses bladder overactivity induced by bladder acetic acid infusion in anesthetized female rats.

             Véronique Guilloteau, Karine Rollet, Marc Guérard, Timothy Westfall, Stefano palea, Philippe Lluel.

            

             Moderated Poster presented on Monday, May 16, 2011 from 8:00 to 10:00.

 

UROsphere's top managers will be present during the meeting. If you wish to meet them, please contact us or contact our US representative.

]]>Auteur de ma newsSat, 14 May 2011 00:00:00 +020024 object1-318http://www.urosphere.com/web/EN/22-actualites.php?id=318UROsphere present scientific results at EAU annual meeting (Vienna, Austria, 18-22 March, 2011) 

 

 

 

The following oral communication will be presented:

  • Experimental effects of sodium hyaluronate and chondroitin sulfate combination in a bladder model.

Presented by Stefano Palea at the IBSA satellite symposium on Saturday March 19th from 17:45 to 19:15.

 

The following poster will be presented:

  • DFL14817 and AMTB inhibit rhythmic bladder contractions under isovolumetric conditions in anesthetized female rats.

Presented by Stefano Palea at Poster session 68:" Bladdder function: news from basic science" to be held on Monday March 21st from 9:15 to 10:45.

 

UROsphere's top managers will be present during the meeting. If you wish to meet them, please contact us
 

 

 

 

 

 

]]>Auteur de ma newsMon, 28 Feb 2011 00:00:00 +010024 object1-312http://www.urosphere.com/web/EN/22-actualites.php?id=312UROsphere presents scientific results at the National Congress of the Italian Society of Urology (Milano, Italy, 17-20 October 2010)We are pleased to announce the presentation of our research results during this meeting “Effects of the association of Hyaluronic Acid and Chondroitin Sulfate at high doses (Ialuril) in a model of induced cystitis in rats.”

UROsphere's top manager will be present during the congress. If you wish to meet them, please contact us.

More information on the congress web site.

]]>Auteur de ma newsTue, 14 Sep 2010 00:00:00 +020024 object1-308http://www.urosphere.com/web/EN/22-actualites.php?id=308UROsphere and CMX Research have formed a pan-Atlantic partnership to offer preclinical to Phase IV contract research servicesThis pan-Atlantic partnership will take advantage of deep expertise in the development of Urology based compounds residing in both companies to efficiently move products from the bench to the bedside.

“We are very enthusiastic about building a comprehensive solution for the Urology drug and device development industry,” comments CMX Research Inc. CEO and practicing Urologist Dr. Richard Casey. “With over 18 years of clinical development experience and 360 trials implemented at CMX Research, coupled with the state-of-the-art in vivo and in vitro pre-clinical models offered through UROsphere, this partnership will be the first of its kind in the field of Urology”.

“UROsphere is excited about joining forces with CMX Research to provide the expertise and ability to develop treatments for urological pathologies from concept through registration and beyond,” explains Dr. Philippe Lluel, CEO of UROsphere. “UROsphere’s vast experience in investigating and validating early stage assets compliments the clinical expertise of CMX Research, providing clients with unique access to expertise across the full spectrum of drug development.”


About UROsphere

UROsphere is an independent Contract Research company specializing in preclinical urogenital and renal assays. The company was founded in 2004 by Dr Philippe Lluel and Dr Stefano Palea, two senior researchers with decades of experience in large pharmaceutical companies testing and developing drug candidates for urological indications.

Through our optimized pharmacology platform, we conduct assays to investigate new therapies and combinations of existing therapies for lower urinary tract (LUTs) pathologies.

UROsphere's headquarters and laboratories are located in Toulouse, France. The company also has a representative in Philadelphia, Pennsylvania, USA.


Contact :
Philippe Lluel, Ph D
CEO
+33 (0)5.61.55.58.04
contact@urosphere.com
Laboratoires - Faculté des Sciences Pharmaceutiques de Toulouse - UPS
35, Chemin des Maraîchers - 31062 Toulouse Cedex 09 - France
http://www.urosphere.com

 



About CMX Research Inc.

CMX Research Inc. is an independent, full service CRO that provides highly experienced clinical project management teams to monitor Phase I-IV clinical research trials across Canada. We excel at fully integrating with our clients’ project teams to ensure that medical research is conducted ethically, effectively and efficiently.

Since 1995 we have completed over 360 Phase I-IV projects with our clients that include biotech, pharmaceutical and medical device companies.

CMX Research Inc. manages the largest urology network in Canada, representing over 100 physicians and 120 coordinators within the research community setting. Our highly experienced clinical investigators and research coordinators cover an array of therapeutic indications with an emphasis in urology.

Contact:
Roger Sharpe, M.B.A.
Director, Business Development
(416) 435-1746
rsharpe@cmxres.com
CMX Research Inc.
http://www.cmxres.com

 

]]>Auteur de ma newsMon, 28 Jun 2010 00:00:00 +020023 object1-297http://www.urosphere.com/web/EN/22-actualites.php?id=297UROsphere presents scientific results at the 16th World Congress of Basic and Clinical Pharmacology (Copenhagen, Denmark, 17-23 July 2010) The following posters will be presented:

  • Comparison of the effects of AdTx1 and tamsulosin on the increase in intra-urethral and arterial pressures induced by phenylephrine in anesthetized male rats.
  • Effects of duloxetine on bladder and external urethral sphincter in anesthetized female guinea-pigs with intravesical acetic acid.
     
  • Stimulation of β3-adrenoceptors inhibits EFS-induced contractions of human isolated urinary bladder.
  • Stimulation of both β2- and β3-adrenoceptors produces relaxation of KCl-induced contractions of mouse isolated urinary bladder.
  • Involvement of both β2- and β3-adrenoceptors in the inhibition of neurogenic contractions of mouse isolated urinary bladder.

UROsphere's top managers will be present during the meeting. If you wish to meet them, please contact us

More information on IUPHAR 2010.

]]>Auteur de ma newsMon, 21 Jun 2010 00:00:00 +020024 object1-301http://www.urosphere.com/web/EN/22-actualites.php?id=301New in vivo model and in vitro assay for stress and mixed incontinenceUROsphere launches two new in vivo experimental model and in vitro assay for stress and mixed incontinence pathologies:

For more information on our assays and models for stress and mixed incontinence, please click here.
 

]]>Auteur de ma newsTue, 11 May 2010 00:00:00 +020023 object1-300http://www.urosphere.com/web/EN/22-actualites.php?id=300UROsphère conçoit des modèles pour valider les médicaments dédiés aux pathologies uro-génitalesAuteur de ma newsTue, 11 May 2010 00:00:00 +020023